Document is current

Article History

Received: 21 February 2019

Accepted: 13 May 2019

First Online: 28 May 2019

Ethics approval and consent to participate

: The analyses presented in this report were conducted on the basis of de-identified demographic, clinical and genome-wide genetic data from patients randomized to CALGB 40101 (NCT00041119). The analysis population was restricted to CALGB 40101 patients who had provided consent to participation in pharmacogenomic research under the auspices of a pharmacogenetic companion study (CALGB 60202). Consent for participation in pharmacogenetic studies was obtained on the basis of written approval from each patient and recorded on a protocol-specific informed consent form. The Alliance for Clinical Trials in Oncology is the responsible party for CALGB 40101 and has given authors permission to use the data for this methods research project. Their contribution has been acknowledged in the paper. It is also noted that these data are available through the database of Genotypes and Phenotypes (dbGaP; Study Accession: phs000807.v1.p1).The clinical parent study CALGB 40101 (NCT00041119) along with all of its correlative sub-studies, including CALGB 60202, were reviewed by the Central Institutional Review Board (CIRB) for the National Cancer Institute ().

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.